There has been a steady increase in A (H1N1) influenza cases in the country with the number touching 93 as four more suspected patients tested positive.
Of the confirmed cases, 61 have been discharged while the remaining are undergoing treatment at identified health facilities. The situation was being monitored, a Health and Family Welfare Ministry official said here on Sunday.
Tuesday, June 30, 2009
Former Drug Controller General of India (DCGI), Dr M Venkateswarlu passed away
The former Drug Controller General of India (DCGI), Dr M Venkateswarlu (61), passed away on Sunday night at Mumbai, Maharashtra, succumbing to a massive heart attack.
Dr Venkateswarlu, who has been ailing with kidney failure for past several months, is acclaimed as the renovator of the Indian pharmaceutical regulatory set up. He was the brain behind various paradigm shifting decisions in his tenure in the Central Drug Standard Control Organisation (CDSCO) as Joint Director and the DCGI.The revision of age old Schedule M norms to update drug manufacturing standards on par with the global Good Manufacturing Practices (GMPs), Schedule Y norms to bring in quality of clinical trial practices up to the standards of the Good Laboratory Practices (GLP) and Good Clinical Practices (GCP) elsewhere has been initiated in his one and a half year stint as DCGI.
Dr Venkateswarlu took charge as the DCGI on August 2006 and continued in the post till his retirement on January 2008. The tenure includes a six months extension of his services as DCGI considering the importance of the tasks pursued by him in the period. However, his action on strict implementation of revised Schedule M and quick actions on the fixed drug combinations (FDCs) sold in the country without the approval of DCGI has invited a lot of debate in the pharma industry."
Monday, June 29, 2009
Workshops in Mumbai - Clinical research, SOPs and Inspections
Tools for Compliance – SOPs Guide to defining need, development and maintenance of SOPs
&
Regulatory Inspections : Preparing for and meeting expectations
17 - 18 July 2009 at The Residence Hotel & Convention Centre & Ramada, Powai, Mumbai
By
Arkus Clinical Trial Support Solutions, Ahmedabad & PharMantra Consulting Services, Hyderabad
Trainers:
Dr. Anupama Ramkumar M.D
Ranjani Nellore, Ph.D., RAC
Cost of the program: Rs. 5500/-per workshop
(Inclusive of course material, lunch and refreshments; discounts available for groups and individuals who register for both workshops)
Who would benefit – Clinical research professionals in sponsor, CRO, SMO companies, principal investigators and site staff engaged in activities requiring compliance with regulatory and GCP requirements.
About the trainers:
Dr Anupama Ramkumar, M.D (Med) is a well known GCP Trainer in India and runs Arkus Clinical Trial Support Solutions, a rapidly growing, training and consulting firm engaged in assisting sponsor companies running their trials in India, helping identify/audit CROs/sites and other vendors for optimal trial conduct and logistics. She has been a part of the clinical research Industry in India since its early days and has herself been an Investigator on Phase 1 trials while working as the Medical Director at Lambda Therapeutic Research, Ahmedabad,India.
Ranjani Nellore, Ph.D. RAC is a regulatory affairs certified professional with over 12 years of pharmaceutical industry experience in USA and India. She has submitted clinical trial applications and INDs to FDA, MHRA, TPD (Canada) and DCGI for several NCEs. She has participated in meetings with the EMEA and US FDA. She is an invited speaker at national and international meetings and renders customized training programs. She has now established PharMantra Consulting Services which provides regulatory consulting services to the global health science industry.
To register, please send email to:Anupama@arkusresearch.com; ranjani@pharmantra. com or
Call - Dr Anupama at 98254 13761 or Dr. Ranjani at 99590 72225
&
Regulatory Inspections : Preparing for and meeting expectations
17 - 18 July 2009 at The Residence Hotel & Convention Centre & Ramada, Powai, Mumbai
By
Arkus Clinical Trial Support Solutions, Ahmedabad & PharMantra Consulting Services, Hyderabad
Trainers:
Dr. Anupama Ramkumar M.D
Ranjani Nellore, Ph.D., RAC
Cost of the program: Rs. 5500/-per workshop
(Inclusive of course material, lunch and refreshments; discounts available for groups and individuals who register for both workshops)
Who would benefit – Clinical research professionals in sponsor, CRO, SMO companies, principal investigators and site staff engaged in activities requiring compliance with regulatory and GCP requirements.
About the trainers:
Dr Anupama Ramkumar, M.D (Med) is a well known GCP Trainer in India and runs Arkus Clinical Trial Support Solutions, a rapidly growing, training and consulting firm engaged in assisting sponsor companies running their trials in India, helping identify/audit CROs/sites and other vendors for optimal trial conduct and logistics. She has been a part of the clinical research Industry in India since its early days and has herself been an Investigator on Phase 1 trials while working as the Medical Director at Lambda Therapeutic Research, Ahmedabad,India.
Ranjani Nellore, Ph.D. RAC is a regulatory affairs certified professional with over 12 years of pharmaceutical industry experience in USA and India. She has submitted clinical trial applications and INDs to FDA, MHRA, TPD (Canada) and DCGI for several NCEs. She has participated in meetings with the EMEA and US FDA. She is an invited speaker at national and international meetings and renders customized training programs. She has now established PharMantra Consulting Services which provides regulatory consulting services to the global health science industry.
To register, please send email to:Anupama@arkusresearch.com; ranjani@pharmantra. com or
Call - Dr Anupama at 98254 13761 or Dr. Ranjani at 99590 72225
Friday, June 26, 2009
Dr. M.G.R Medical University M. Pharm counselling rescheduled
Dr. M.G.R Medical University announced that the M.Pharm scheduled for23.06.09 gets postponed due to administrative reasons.
The counselling has been rescheduled to the third week of July. Individual call letters will be sent to the eligible candidates only.
A(H1N1) cases up to 78
Five more people have tested positive for the A (H1N1) influenza in the past 24 hours, taking the total number of confirmed cases to 78. Among the new cases, two are from Gurgaon, and one each from Delhi, Pune and Kolkata.
Of the two cases in Gurgaon, one is a 19-year-old boy who travelled from Minnesota, U.S., to London, staying there for 10 days, and then reached Delhi on June 21. The second case from Gurgaon is a 10-year-old girl who arrived from New York on June 19. Both of them were under home quarantine, and are being shifted to a health facility after testing positive.
The case from Delhi is a six-year-old girl who arrived from Miami, U.S., transiting Frankfurt, on June 18. Both her parents who travelled with her have already tested positive and are undergoing treatment.
In Pune, it is a 29-year-old man who travelled from San Francisco, U.S., transiting Hong Kong, and reached Mumbai on June 24. He developed fever, chills, rigor, sore throat and headache, and reported to an identified health facility on the same day.
Of the two cases in Gurgaon, one is a 19-year-old boy who travelled from Minnesota, U.S., to London, staying there for 10 days, and then reached Delhi on June 21. The second case from Gurgaon is a 10-year-old girl who arrived from New York on June 19. Both of them were under home quarantine, and are being shifted to a health facility after testing positive.
The case from Delhi is a six-year-old girl who arrived from Miami, U.S., transiting Frankfurt, on June 18. Both her parents who travelled with her have already tested positive and are undergoing treatment.
In Pune, it is a 29-year-old man who travelled from San Francisco, U.S., transiting Hong Kong, and reached Mumbai on June 24. He developed fever, chills, rigor, sore throat and headache, and reported to an identified health facility on the same day.
Saturday, June 20, 2009
Update on Swine Flu in India
Six new swine flu cases were reported on Friday — three from Delhi, two from Bangalore and one from Mumbai — taking the total number of positive cases across the country to 50.
Total number of positive cases across the country rises to 50
16 people have been discharged after being successfully treated for swine flu
So far, samples of 407 people have been tested. Of the 50 positive cases, five are indigenous.
World Health Organisation has reported 39,620 laboratory confirmed cases of swine flu from 89 countries till June 17. There have been 167 deaths. Thailand has reported community spread with 310 laboratory confirmed cases.
Health screening of passengers coming from affected countries is continuing at international airports. As many as 48,047 passengers were screened on Thursday, of whom 25,589 were from the affected countries.
Advinus Therapeutics files its First Investigational New Drug Application
Advinus Therepeutics announced that it has filed its first IND with the DCGI last week for a type 2 diabetes molecule and expects to commence phase 1 clinical trials shortly after approval.
Dr. Rashmi Barbhaiya, the CEO and Managing Director of the company stated, "Our drug discovery operations have now been expanded to almost 3 folds of what they were. The new facility will give us a lot of room for growth of internal programmes and innovative models for future partnerships. I am very proud that in less than 3 years we have been able to file our first IND for approval of clinical trials which is a combined effort of both our Pune and Bangalore operations."
Dr. Kasim Mookhtiar, Chief Scientific Officer of the company added, that "the filing of Advinus' first IND marks the beginning of the company's delivery of a pipeline of innovative products that addresses large unmet medical needs."
Dr. Rashmi Barbhaiya, the CEO and Managing Director of the company stated, "Our drug discovery operations have now been expanded to almost 3 folds of what they were. The new facility will give us a lot of room for growth of internal programmes and innovative models for future partnerships. I am very proud that in less than 3 years we have been able to file our first IND for approval of clinical trials which is a combined effort of both our Pune and Bangalore operations."
Dr. Kasim Mookhtiar, Chief Scientific Officer of the company added, that "the filing of Advinus' first IND marks the beginning of the company's delivery of a pipeline of innovative products that addresses large unmet medical needs."
Tuesday, June 16, 2009
Dedicated courses on medical devices sector at NIPER Ahmedabad
The National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, one of the six new NIPERs established in different parts of the country, is planning to initiate courses to develop human resources to enhance the performance of medical devices industry in the country. The institute will be one of the first to introduce a dedicated course for medical devices technology, according to NIPER sources.
The institute, which is expected to commence operations in next couple of months, has identified the scope of emerging medical devices segment in the country and has plans to set up operations in three specific segments to help the industry. The identified segments are - setting up academic centres, establishing a testing facility for medical devices with testing equipments, testing models for efficacy and quality control studies and building up pre-clinical and clinical study facilities required for medical devices (class 2B and III) for the industry.The institute has recently conducted analysis on the sector to identify the prospects of medical devices industry and need for human resources.
The draft report has been submitted to the Department of Pharmaceuticals and the department is seeking feedback from the industry on the report. Based on the feedback the institute will submit its final report to the department which, in turn, is expected to offer additional funds to set up the infrastructure at Ahmedabad to support the medical devices industry, informed Dr Harish Padh, project director, NIPER-Ahmedabad and director, B V Patel Pharmaceutical Education and Research Development (PERD) Centre.
Clinical Trial Registration in India become mandatory
The Central Drugs Standard Control Organisation (CDSCO) has made it mandatory the registration of all clinical trials in the ICMR Trial Registry with effect from June 15, as part of streamlining the trials sector which has been largely unregulated.
"It has been decided to make registration of clinical trial mandatory with effect from June 15, 2009, which will be applicable for clinical trials initiated after June 15, 2009. Accordingly, while granting permission for clinical trials, applicants are now being informed that registration of clinical trial in ICMR Clinical Trial Registry www.ctri.in before its initiation will be mandatory from June 15, 2009," the notice from the DCGI office said.
The DTAB had approved a number of proposals including incorporation of a new Schedule Y1 to the Drugs and Cosmetics Rules 1945 to specify all aspects regarding trials. The DTAB has also given green signal for proposals like announcing guidelines, penalty provisions for defaults, registration of ethics committees and on-site audits of trials, which the DCGI office will now be carrying out with the help of specially assigned teams, sources said.
While granting permission for conducting trials, the DCGI office henceforth will advise the applicants to register them in the web-based registry. The registration of trials has been voluntary so far and among the hundreds of ongoing trials, not even 25 per cent of them have registered so far. Besides, the DCGI office have also prepared guidelines for registration of ethics committees so that some uniform pattern can be worked out and they can be made more effective.
Another proposal is to ask the trial companies to get the finger-prints of all volunteers in phase-III trials and share the data between the CROs. This will ensure that the same man is not going for another trial by another company, after being a subject in one trial.The number of trials that a principal investigator also will be limited for more effective end results, sources said.
Rimonabant - Anti-Obesity Drug to be banned in India
Rimonabant, the anti-obesity drug being sold in India by about 17 companies under different names like Rimoslim, Slimona etc., will soon by banned in India.
Rimonabant (SR141716) is a neurokinin-3 antagonist and selective cannabinoid (CB1) receptor antagonist currently being researched and developed under the proprietary name, Acomplia, by Sanofi-Aventis. The chemical name is N-piperino5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3carboxamide
Rimonabant acts by selectively blocking the cannabinoid-1 receptors with resultant central and metabolic peripheral effects, thereby decreasing food intake.
In the UK, was available beginning in July 2006. As of 2008, the drug was available in 56 countries. On October 23, 2008, the European Medicines Agency (EMEA) released a press release stating that its Committee for Medical Products for Human Use (CHMP) had concluded that the benefits of Acomplia no longer outweighed its risks and subsequently recommended that the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating that the drug had been suspended.
Rimonabant (SR141716) is a neurokinin-3 antagonist and selective cannabinoid (CB1) receptor antagonist currently being researched and developed under the proprietary name, Acomplia, by Sanofi-Aventis. The chemical name is N-piperino5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3carboxamide
Rimonabant acts by selectively blocking the cannabinoid-1 receptors with resultant central and metabolic peripheral effects, thereby decreasing food intake.
In the UK, was available beginning in July 2006. As of 2008, the drug was available in 56 countries. On October 23, 2008, the European Medicines Agency (EMEA) released a press release stating that its Committee for Medical Products for Human Use (CHMP) had concluded that the benefits of Acomplia no longer outweighed its risks and subsequently recommended that the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating that the drug had been suspended.
Friday, June 12, 2009
World now at the start of 2009 influenza pandemic
In late April, WHO announced the emergence of a novel influenza A virus.
This particular H1N1 strain has not circulated previously in humans. The virus is entirely new.
The virus is contagious, spreading easily from one person to another, and from one country to another. As of today, nearly 30,000 confirmed cases have been reported in 74 countries.
This is only part of the picture. With few exceptions, countries with large numbers of cases are those with good surveillance and testing procedures in place.
Spread in several countries can no longer be traced to clearly-defined chains of human-to-human transmission. Further spread is considered inevitable.
I have conferred with leading influenza experts, virologists, and public health officials. In line with procedures set out in the International Health Regulations, I have sought guidance and advice from an Emergency Committee established for this purpose.
On the basis of available evidence, and these expert assessments of the evidence, the scientific criteria for an influenza pandemic have been met.
I have therefore decided to raise the level of influenza pandemic alert from phase 5 to phase 6.
The world is now at the start of the 2009 influenza pandemic.
We are in the earliest days of the pandemic. The virus is spreading under a close and careful watch.
No previous pandemic has been detected so early or watched so closely, in real-time, right at the very beginning. The world can now reap the benefits of investments, over the last five years, in pandemic preparedness.
We have a head start. This places us in a strong position. But it also creates a demand for advice and reassurance in the midst of limited data and considerable scientific uncertainty.
....On present evidence, the overwhelming majority of patients experience mild symptoms and make a rapid and full recovery, often in the absence of any form of medical treatment.Worldwide, the number of deaths is small. Each and every one of these deaths is tragic, and we have to brace ourselves to see more. However, we do not expect to see a sudden and dramatic jump in the number of severe or fatal infections.
We know that the novel H1N1 virus preferentially infects younger people. In nearly all areas with large and sustained outbreaks, the majority of cases have occurred in people under the age of 25 years.
In some of these countries, around 2% of cases have developed severe illness, often with very rapid progression to life-threatening pneumonia.
Most cases of severe and fatal infections have been in adults between the ages of 30 and 50
years.
This pattern is significantly different from that seen during epidemics of seasonal influenza, when most deaths occur in frail elderly people.
Many, though not all, severe cases have occurred in people with underlying chronic conditions. Based on limited, preliminary data, conditions most frequently seen include respiratory diseases, notably asthma, cardiovascular disease, diabetes, autoimmune disorders, and obesity.
At the same time, it is important to note that around one third to half of the severe and fatal infections are occurring in previously healthy young and middle-aged people.
Without question, pregnant women are at increased risk of complications. This heightened risk takes on added importance for a virus, like this one, that preferentially infects younger age groups.
Finally, and perhaps of greatest concern, we do not know how this virus will behave under conditions typically found in the developing world. To date, the vast majority of cases have been detected and investigated in comparatively well-off countries. ...
(Source WHO. Excerpted from the Statement to the press by WHO Director-General Dr Margaret Chan 11 June 2009 )
Pharmacopoeia available with Pharmexcil, Hyderabad
Pharmacopoeia have been procured at Pharmexcil, Hyderabad with the fund support from Dept. of Pharmaceuticals, Govt. of India.
1. Indian Pharmacopoeia 2007 (IP) 3 Volumes
2. Ayurvedic Pharmacopoeia of India2001 Part I - Volume I, III & IV
3. British Pharmacopoeia 2009 (BP) 4 Volumes
4. BP Veterinary 2009 (BP- Vet)
5. USP NF 2009 (USP) 3 Volumes
6. European Pharmacopoeia 2008 (EP6.0) 2 Volumes
European Pharmacopoeia 2008 (EP6.1, 6.2) 2 Volumes supplements
European Pharmacopoeia 2009 (EP6.3, 6.4, 6.5) 3 Volumes supplements
7. Pharmacopoeia of China 2005 (Chinese Pharmacopoeia) 3 Volumes
8. Extra Pharmacopoeia 2007 (Martindale 35th Edition) 2 Volumes
Other Reference Books:
1. Merck Index (Merck Index – 14th Edition)
2. Physician Desk Reference 2009 (PDR-63rd Edition)
People interested in availing the facility for Monograph references may contact by sending email to info@pharmexcil.com The information/copies of the monographs will be provided at a nominal service charge.
1. Indian Pharmacopoeia 2007 (IP) 3 Volumes
2. Ayurvedic Pharmacopoeia of India2001 Part I - Volume I, III & IV
3. British Pharmacopoeia 2009 (BP) 4 Volumes
4. BP Veterinary 2009 (BP- Vet)
5. USP NF 2009 (USP) 3 Volumes
6. European Pharmacopoeia 2008 (EP6.0) 2 Volumes
European Pharmacopoeia 2008 (EP6.1, 6.2) 2 Volumes supplements
European Pharmacopoeia 2009 (EP6.3, 6.4, 6.5) 3 Volumes supplements
7. Pharmacopoeia of China 2005 (Chinese Pharmacopoeia) 3 Volumes
8. Extra Pharmacopoeia 2007 (Martindale 35th Edition) 2 Volumes
Other Reference Books:
1. Merck Index (Merck Index – 14th Edition)
2. Physician Desk Reference 2009 (PDR-63rd Edition)
People interested in availing the facility for Monograph references may contact by sending email to info@pharmexcil.com The information/copies of the monographs will be provided at a nominal service charge.
Dr. M.G.R University M.Pharm Counselling 2009-2010
Dr. M.G. R University has announced the date of counselling for admission to M.Pharmacy for the year 2009-2010
Date: 23.06.09
Time: 10.00 AM
Candidates are asked to be present at counselling venue (Kilpauk Medical College Auditorium,Kilpauk,Chennai-10) 1hour prior to the beginning of the Counselling.
Seat matrix of the Counselling for M.Pharm courses will be displayed prior to the counselling
Dr. M.G. R University M.Pharm 2009 Merit List
Date: 23.06.09
Time: 10.00 AM
Candidates are asked to be present at counselling venue (Kilpauk Medical College Auditorium,Kilpauk,Chennai-10) 1hour prior to the beginning of the Counselling.
Seat matrix of the Counselling for M.Pharm courses will be displayed prior to the counselling
Dr. M.G. R University M.Pharm 2009 Merit List
Dr. M.G. R University M.Pharm 2009 - Merit List
Dr. M.G. R University has released the Merit list of the candidates who have applied for admission to M.Pharm programs for the year 2009-2010.
Sugantha Lakshmi S is the topper followed by Jothikumar K and Vasanthy L.
Click here to see the entire list.
Monday, June 8, 2009
Certificate Course in PATENT FUNDAMENTALS
Academy of Intellectual Property Studies is providing a certificate course in PATENT FUNDAMENTALS
The course will provide an in-depth understanding of the theory underlying patents. It will guide participants on the role of patents, patentability requirements and the major concepts of Patent Law. The Indian Patent Act, International and Comparative Patent Law, Filing and Prosecution of patents in India, PCT filing etc. will also be studied. Hands-on training will be provided on Prior-art Search and Specification Drafting, and these technical sessions will ensure that the participant has gained sufficient expertise to contribute effectively at the work-place. The faculty includes practicing professionals who are experts in the field, dealing with patenting issues on a daily basis.
Duration 5 months . (Part time)
Commencement June 27, 2009 .
For details, please mail info@aips.ac.in
The course will provide an in-depth understanding of the theory underlying patents. It will guide participants on the role of patents, patentability requirements and the major concepts of Patent Law. The Indian Patent Act, International and Comparative Patent Law, Filing and Prosecution of patents in India, PCT filing etc. will also be studied. Hands-on training will be provided on Prior-art Search and Specification Drafting, and these technical sessions will ensure that the participant has gained sufficient expertise to contribute effectively at the work-place. The faculty includes practicing professionals who are experts in the field, dealing with patenting issues on a daily basis.
Duration 5 months . (Part time)
Commencement June 27, 2009 .
For details, please mail info@aips.ac.in
Meeting Global Market Challenges- An interactive session with Exporters
Pharmexcil is organizing a Seminar titled “Meeting Global Market Challenges- An interactive session with Exporters” for its members on 27th June 2009 at Hotel GRT Grand, Chennai. The programme is scheduled from 9.30 am till 1.45 p.m. followed by lunch.
This interaction would be mainly focussing on
Ø Export potential of Indian Pharmaceuticals in global market place
Ø Regulatory issues and product registrations
Ø Export Credit
Ø Pre-shipment Inspection related issues.
In short the interaction will focus on tools to cope with current issues and problems confronting pharma companies, especially SMEs and will give them a forum to present their valuable feedback and views.
Members of PHARMEXCIL can participate in this Seminar and take the advantage of direct interaction with the experts who have been invited to speak on important topics of concern.
The registration fee is Rs500/- and can be paid through DD/at par Cheque in favour of Pharmaceuticals Export Promotion Council, payable at Hyderabad.
Here is the Registration Form and Tentative Programme schedule.
Filled in Registration forms are to be sent to rodelhi@pharmexcil.com by e-mail or Fax it to-011-41536658.
This interaction would be mainly focussing on
Ø Export potential of Indian Pharmaceuticals in global market place
Ø Regulatory issues and product registrations
Ø Export Credit
Ø Pre-shipment Inspection related issues.
In short the interaction will focus on tools to cope with current issues and problems confronting pharma companies, especially SMEs and will give them a forum to present their valuable feedback and views.
Members of PHARMEXCIL can participate in this Seminar and take the advantage of direct interaction with the experts who have been invited to speak on important topics of concern.
The registration fee is Rs500/- and can be paid through DD/at par Cheque in favour of Pharmaceuticals Export Promotion Council, payable at Hyderabad.
Here is the Registration Form and Tentative Programme schedule.
Filled in Registration forms are to be sent to rodelhi@pharmexcil.com by e-mail or Fax it to-011-41536658.
Sunday, June 7, 2009
Swine Flu alert in Andhra Pradesh - Outbreak in India ?
Andhra Pradesh went on a health alert on Saturday in the wake of a looming threat of outbreak of influenza A(H1N1) flu virus, after authorities detected the country’s first case of the virus getting transmitted to local public from an international passenger.
Health authorities said a 26-year-old man, who had no international travel history, had tested positive for the virus strain. His brother, who flew into Hyderabad in a British Airways flight (BA 277) on May 31, has already been isolated after testing positive. Interestingly, a woman and her daughter who travelled by the same flight also were found to be affected by the virus. The woman (31) and daughter aged four-and-a-half years have also been quarantined. This takes the total number of isolated virus positive cases in Government Chest Hospital here to five.
Earlier, the country’s first confirmed flu patient was treated and discharged from the hospital.
Alarmed over the developments, Chief Minister Y.S. Rajasekhara Reddy took up the issue with authorities concerned, in a video conference, where it was decided to screen all the inbound passengers from abroad. The government has also decided to create quarantine facilities in districts – isolation wards with at least 10 beds in every district, Health Secretary L.V. Subramanyam said.
A team from the National Institute of Communicable Diseases (NICD) from New Delhi is also arriving here to help authorities chalk out a contingency plan in case of an outbreak.
The latest case of the young man testing positive is causing concern since he had attended a series of interviews in the last few days in Hyderabad and the authorities fear that he could have transmitted the virus to others. Authorities are also administering anti-viral drugs to those seated in the nearby rows in the British Airways aircraft.
Referring to compulsory screening of all passengers, authorities said anyone resisting or avoiding the screening would be arrested.
Spread of virus
That it is going to be a long drawn effort to contain spread of virus was indicated when Mr. Subramanyam pointed out that “the virus could become aggressive during winter”.
Health authorities said a 26-year-old man, who had no international travel history, had tested positive for the virus strain. His brother, who flew into Hyderabad in a British Airways flight (BA 277) on May 31, has already been isolated after testing positive. Interestingly, a woman and her daughter who travelled by the same flight also were found to be affected by the virus. The woman (31) and daughter aged four-and-a-half years have also been quarantined. This takes the total number of isolated virus positive cases in Government Chest Hospital here to five.
Earlier, the country’s first confirmed flu patient was treated and discharged from the hospital.
Alarmed over the developments, Chief Minister Y.S. Rajasekhara Reddy took up the issue with authorities concerned, in a video conference, where it was decided to screen all the inbound passengers from abroad. The government has also decided to create quarantine facilities in districts – isolation wards with at least 10 beds in every district, Health Secretary L.V. Subramanyam said.
A team from the National Institute of Communicable Diseases (NICD) from New Delhi is also arriving here to help authorities chalk out a contingency plan in case of an outbreak.
The latest case of the young man testing positive is causing concern since he had attended a series of interviews in the last few days in Hyderabad and the authorities fear that he could have transmitted the virus to others. Authorities are also administering anti-viral drugs to those seated in the nearby rows in the British Airways aircraft.
Referring to compulsory screening of all passengers, authorities said anyone resisting or avoiding the screening would be arrested.
Spread of virus
That it is going to be a long drawn effort to contain spread of virus was indicated when Mr. Subramanyam pointed out that “the virus could become aggressive during winter”.
(from The Hindu)
Swine Swine go away
Swine Swine go away
Better don't come our way
Healthy do we wanna stay
No hefty doctor bills to pay
Swine Swine go away
Better don't come our way.
(...just heard a kid reciting the original rhyme while I was talking to someone on Swine Flu... could not resist the remix idea that popped up in my mind that time.. he he he)
Better don't come our way
Healthy do we wanna stay
No hefty doctor bills to pay
Swine Swine go away
Better don't come our way.
(...just heard a kid reciting the original rhyme while I was talking to someone on Swine Flu... could not resist the remix idea that popped up in my mind that time.. he he he)
Saturday, June 6, 2009
Russia a "potential superpower" in clinical trials
Russia has now matured beyond being an emerging market and is now "a growing potential superpower", according to Synergy Research Group, which formed this conclusion after attending a conference.
The Russia-based contract research organisation (CRO) also believes that there is no competition between Russia, India and China for international clinical trials.
In addition the CRO claims that the clinical trial market has so far been unaffected by the economic downturn. Two reasons are cited for this: the length of the drug development cycle and the "elasticity of a medicine".
The CRO goes on to claim that Russia can benefit from the economic downturn by helping small to mid-sized companies cut development times and reach the market quicker.
Source: Pharma Update
The Russia-based contract research organisation (CRO) also believes that there is no competition between Russia, India and China for international clinical trials.
In addition the CRO claims that the clinical trial market has so far been unaffected by the economic downturn. Two reasons are cited for this: the length of the drug development cycle and the "elasticity of a medicine".
The CRO goes on to claim that Russia can benefit from the economic downturn by helping small to mid-sized companies cut development times and reach the market quicker.
Source: Pharma Update
Friday, June 5, 2009
Pharm D approval for 2009
Swami Vivekananda College of Pharmacy in Elayampalayam in Namakkal district in Tamil Nadu is waiting for the approval of AICTE for starting the new Pharm D course from this academic year.
Thursday, June 4, 2009
Award for Companies who secure Patents in 2008-09
In order to encourage Patent Knowledge utilization by Pharma Exporters, it is proposed to present awards to the PHARMEXCIL members securing the patents from any Patent Granting Authority in the year 2008-09. These awards are sponsored with support from Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India.
Patents under the following 7 product groups under LSM / SME categories will be considered for awards separately:
Ø Bulk Drugs / APIs
Ø Formulations
Ø Biotech Products
Ø Herbal / ASU / Nutraceuticals
Ø Medical Devices/ Surgicals / Diagnostics
Ø Clinical Research/Trails
Ø NCEs / Drug Discovery
Members who have been granted patent awards are advised to send the details of their patents received in 2008-09 to Pharmexcil as per enclosed proforma.
The awards will be declared based on the recommendations of the expert panel to be constituted for this purpose.
Patents under the following 7 product groups under LSM / SME categories will be considered for awards separately:
Ø Bulk Drugs / APIs
Ø Formulations
Ø Biotech Products
Ø Herbal / ASU / Nutraceuticals
Ø Medical Devices/ Surgicals / Diagnostics
Ø Clinical Research/Trails
Ø NCEs / Drug Discovery
Members who have been granted patent awards are advised to send the details of their patents received in 2008-09 to Pharmexcil as per enclosed proforma.
The awards will be declared based on the recommendations of the expert panel to be constituted for this purpose.
Swine Flu in Andhra Pradesh
Two cases have been identified so far in the state of Andhra.
Andhra Pradesh has the dubious distinction of reporting the first ever Swine Flu case in India. On May 16, 2009, a 23-year old student returning from New York was identified to be the first to be infected with Swine Flu and then recently a 20-year Medical Student who returned home to Hyderabad from Chicago was identified to be infected.
The medico student has been admitted to a Government hospital in Erragadda and is being administered with Oseltamivir.
State Coordinator for A(H1N1) flu virus Dr. K. Subhakar said “He will be kept on this regimen for five days. His viral load will be checked regularly by sending smear samples to NICD. Already our doctors have treated a positive H1N1 patient and that experience will come in handy now,”
The authorities are scrutinising the list of co-passengers on the BA flight. The doctors have asked the co-passengers to contact (040-2381-4939/ 92461-57447) in case they develop flu-like symptoms.
Swine Flu in Tamilnadu
Andhra Pradesh has the dubious distinction of reporting the first ever Swine Flu case in India. On May 16, 2009, a 23-year old student returning from New York was identified to be the first to be infected with Swine Flu and then recently a 20-year Medical Student who returned home to Hyderabad from Chicago was identified to be infected.
The medico student has been admitted to a Government hospital in Erragadda and is being administered with Oseltamivir.
State Coordinator for A(H1N1) flu virus Dr. K. Subhakar said “He will be kept on this regimen for five days. His viral load will be checked regularly by sending smear samples to NICD. Already our doctors have treated a positive H1N1 patient and that experience will come in handy now,”
The authorities are scrutinising the list of co-passengers on the BA flight. The doctors have asked the co-passengers to contact (040-2381-4939/ 92461-57447) in case they develop flu-like symptoms.
Swine Flu in Tamilnadu
Wednesday, June 3, 2009
Drug Information Centers in India
Drug Information Centers in India
Assam
Institute of PharmacyAssam Medical College, Dibrugarh – 786 002, ASSAM, INDIA
PH: 0373-2300903; 2301666 Fax: 2300080E-mail: dicassam@gmail.com, dic_amc@yahoo.com
Chhattisgarh
Institute of Pharmacy, Chattisgarh State Pharmacy Council, Quarter No. –77, Sector No. – 3, Geetanjali Nagar, RAIPUR (ChhattisgarhState), INDIATel: (0771) 2444591 Fax: (0771) 2444591E-mail: dicraipur@gmail.com, dicraipur@yahoo.com
Haryana
Lord Shiva College of Pharmacy, Near Civil Hospital, Sirsa-125055, HARYANA, INDIA
Tel: (01666) 240057 Fax: (01666) 242695E-mail: dicharyana@gmail.com, dicsirsa@yahoo.co.in
Goa
Hindu Pharmacy, Cunha Rivara Road, P.B. No. 149, Panaji, Goa – 403001PH: 0832-2223176; 2432903 Fax – 22237776E-mail: dicgoa@gmail.com & dicpanaji@yahoo.com
Rajasthan
Rajasthan Pharmacy Council, Govt. Dispensary Campus, Sardar Patel Marg, Jaipur – 302006 PH: 0141-2228600 Fax: 2223041E-mail: dicrspc@gmail.com
in co-ordination with
Lal Bahudur Shastri College of Pharmacy, Udaymarg, Tilaknagar, Jaipur – 302004, RAJASTHAN, INDIAPH: (0141) 2620517, 3258229 Fax: (0141) 2620517
E-mail: dicjaipur@gmail.com, dicjaipur@yahoo.com.
Independent DIC’s in India
1. CDMU Documentation Center, Calcutta
2. Drug Information Center, Maharashtra State Pharmacy Council, Maharashtra
3. Andhra Pradesh State Pharmacy Council, Andhra Pradesh
4. Karnataka State Pharmacy Council (KSPC), Bangalore, Karnataka
5. JSS, Ooty,
6. Pharma Information Center, Tamilnadu, Chennai
Hospital attached DIC’s with Clinical Pharmacy Services
• Christian Medical College Hospital Vellore, Tamilnadu
• Drug Information Center, (KSPC), Victoria Hospital, Bangalore, Karnataka
• Drug Information Center, (KSPC), Bowring & Lady Curzon Hospital, Bangalore, Karnataka
• Department of pharmacy practice, Chidambaram, Tamilnadu
• Department of Pharmacy Practice, National institute of Pharmaceutical Education and Research (NIPER), Chandigarh
• Jawaharlal Nehru Medical College Hospital (JNMC), Belgaum, Karnataka
• JSS, Mysore, Karnataka• JSS, Ooty, Tamilnadu
• N.R.S. Medical College & Hospital, Calcutta
• Kempagowda Institute of Medical Sciences (KIMS), Bangalore, Karnataka
• Kasturba Medical College (KMC), Manipal, Karnataka
• Poison Information Center, All India Institute of Medical Sciences (AIIMS), Delhi
• Poisons Information Centre, National Institute of Occupational Health, Ahmedabad
• Dept of Toxicology, (Incl. Poison Information & Laboratory Services) Amrita Institute of Medical Sciences & Research, Cochin
• Toxicology & IMCU Unit, Government General Hospital, Chennai
• Sri Ramachandra Hospital, Porur, Chennai
• Sri Ramakrishna Mission Hospital, Coimbatore, TamilNadu
• Trivandrum Medical College, Trivandrum, Kerala
Assam
Institute of PharmacyAssam Medical College, Dibrugarh – 786 002, ASSAM, INDIA
PH: 0373-2300903; 2301666 Fax: 2300080E-mail: dicassam@gmail.com, dic_amc@yahoo.com
Chhattisgarh
Institute of Pharmacy, Chattisgarh State Pharmacy Council, Quarter No. –77, Sector No. – 3, Geetanjali Nagar, RAIPUR (ChhattisgarhState), INDIATel: (0771) 2444591 Fax: (0771) 2444591E-mail: dicraipur@gmail.com, dicraipur@yahoo.com
Haryana
Lord Shiva College of Pharmacy, Near Civil Hospital, Sirsa-125055, HARYANA, INDIA
Tel: (01666) 240057 Fax: (01666) 242695E-mail: dicharyana@gmail.com, dicsirsa@yahoo.co.in
Goa
Hindu Pharmacy, Cunha Rivara Road, P.B. No. 149, Panaji, Goa – 403001PH: 0832-2223176; 2432903 Fax – 22237776E-mail: dicgoa@gmail.com & dicpanaji@yahoo.com
Rajasthan
Rajasthan Pharmacy Council, Govt. Dispensary Campus, Sardar Patel Marg, Jaipur – 302006 PH: 0141-2228600 Fax: 2223041E-mail: dicrspc@gmail.com
in co-ordination with
Lal Bahudur Shastri College of Pharmacy, Udaymarg, Tilaknagar, Jaipur – 302004, RAJASTHAN, INDIAPH: (0141) 2620517, 3258229 Fax: (0141) 2620517
E-mail: dicjaipur@gmail.com, dicjaipur@yahoo.com.
Independent DIC’s in India
1. CDMU Documentation Center, Calcutta
2. Drug Information Center, Maharashtra State Pharmacy Council, Maharashtra
3. Andhra Pradesh State Pharmacy Council, Andhra Pradesh
4. Karnataka State Pharmacy Council (KSPC), Bangalore, Karnataka
5. JSS, Ooty,
6. Pharma Information Center, Tamilnadu, Chennai
Hospital attached DIC’s with Clinical Pharmacy Services
• Christian Medical College Hospital Vellore, Tamilnadu
• Drug Information Center, (KSPC), Victoria Hospital, Bangalore, Karnataka
• Drug Information Center, (KSPC), Bowring & Lady Curzon Hospital, Bangalore, Karnataka
• Department of pharmacy practice, Chidambaram, Tamilnadu
• Department of Pharmacy Practice, National institute of Pharmaceutical Education and Research (NIPER), Chandigarh
• Jawaharlal Nehru Medical College Hospital (JNMC), Belgaum, Karnataka
• JSS, Mysore, Karnataka• JSS, Ooty, Tamilnadu
• N.R.S. Medical College & Hospital, Calcutta
• Kempagowda Institute of Medical Sciences (KIMS), Bangalore, Karnataka
• Kasturba Medical College (KMC), Manipal, Karnataka
• Poison Information Center, All India Institute of Medical Sciences (AIIMS), Delhi
• Poisons Information Centre, National Institute of Occupational Health, Ahmedabad
• Dept of Toxicology, (Incl. Poison Information & Laboratory Services) Amrita Institute of Medical Sciences & Research, Cochin
• Toxicology & IMCU Unit, Government General Hospital, Chennai
• Sri Ramachandra Hospital, Porur, Chennai
• Sri Ramakrishna Mission Hospital, Coimbatore, TamilNadu
• Trivandrum Medical College, Trivandrum, Kerala
Pharm. D admission in Vinayaka Missions, Salem
Pharm. D (Doctor in Pharmacy)
Duration : 6 Years ( 5 Years of Study and one year Internship)
Eligibility :
1. A pass in 10 +2 examination with physics and chemistry compulsory
subjects along with either Mathematics or Biology (Botany or Zoology).
(or)
2. A pass in D.Pharm
Pharm. D (Post Baccalaureate)
Duration : 3 Years( 2 Years of Study and one year Internship)
Eligibility : A pass in B.Pharm Degree Course
Click here for application form
Contact:
ADMISSION CELL,
VINAYAKA MISSIONS UNIVERSITY,
15, Bank Street.
Kilpauk, Chennai- 600 010.Tamilnadu
Cell: 09383555060, 09841096255
Ph: 044 - 26451002,42989006,42989000
Fax: 044 - 26451006.
Duration : 6 Years ( 5 Years of Study and one year Internship)
Eligibility :
1. A pass in 10 +2 examination with physics and chemistry compulsory
subjects along with either Mathematics or Biology (Botany or Zoology).
(or)
2. A pass in D.Pharm
Pharm. D (Post Baccalaureate)
Duration : 3 Years( 2 Years of Study and one year Internship)
Eligibility : A pass in B.Pharm Degree Course
Click here for application form
Contact:
ADMISSION CELL,
VINAYAKA MISSIONS UNIVERSITY,
15, Bank Street.
Kilpauk, Chennai- 600 010.Tamilnadu
Cell: 09383555060, 09841096255
Ph: 044 - 26451002,42989006,42989000
Fax: 044 - 26451006.
Swine flu In Tamilnadu: search on for co-passengers
With the first case of A(H1N1) making its entry into Tamil Nadu, the mammoth task of identifying other air passengers, who might have been in contact with the two persons who tested positive, has begun.
In accordance, the Directorate of Public Health has worked out an intensive strategy to identify the persons who travelled with the family of three, two of whom tested positive for the A(H1N1), and are quarantined at the Coimbatore Medical College.
According to the Union Ministry of Health, the blood and serum tests of a 35-year-old woman and her five-year-old son came up positive for the A(H1N1) virus on Monday. The daughter, who accompanied them, is negative, but remains in quarantine because of prolonged contact with the family. The family admitted themselves to the quarantine ward of the CMC on May 28 after coming down with flu-like symptoms. They had reached Chennai from Boston, United States, on May 27. From there, they took a flight to Coimbatore on May 28 to go to their house at Kalapatti on the city outskirts.
Village health nurses will keep a watch on the family’s house, Deputy Director of Health Services V. Vijayalakshmi said on Tuesday. The Coimbatore Corporation is being informed of the addresses of other passengers who had travelled by the local flight along with the family. Of the 55 passengers on the Kingfisher flight from Chennai to Coimbatore, the health authorities had traced about 43 persons by Tuesday evening. Dr. Vijayalakshmi said 28 of them were from Coimbatore and five, including the quarantined family, were from the Coimbatore rural limits. Four persons were residents of Chennai and another four belonged to Chengelput. One male passenger belonged to Palakkad in Kerala. Dr. Vijayalakshmi said he was contacted over phone and told to remain at home for a week and not to mingle with anyone in the neighbourhood. The local health authorities there were also informed. Of the 12 untraceable passengers, four were foreign nationals from Los Angeles, U.S. Efforts were on to locate them with the help of their contact numbers provided by the airport authorities in Chennai.
Swine flu cases in Tamilnadu
Swine Flu in Andhra Pradesh
In accordance, the Directorate of Public Health has worked out an intensive strategy to identify the persons who travelled with the family of three, two of whom tested positive for the A(H1N1), and are quarantined at the Coimbatore Medical College.
According to the Union Ministry of Health, the blood and serum tests of a 35-year-old woman and her five-year-old son came up positive for the A(H1N1) virus on Monday. The daughter, who accompanied them, is negative, but remains in quarantine because of prolonged contact with the family. The family admitted themselves to the quarantine ward of the CMC on May 28 after coming down with flu-like symptoms. They had reached Chennai from Boston, United States, on May 27. From there, they took a flight to Coimbatore on May 28 to go to their house at Kalapatti on the city outskirts.
Village health nurses will keep a watch on the family’s house, Deputy Director of Health Services V. Vijayalakshmi said on Tuesday. The Coimbatore Corporation is being informed of the addresses of other passengers who had travelled by the local flight along with the family. Of the 55 passengers on the Kingfisher flight from Chennai to Coimbatore, the health authorities had traced about 43 persons by Tuesday evening. Dr. Vijayalakshmi said 28 of them were from Coimbatore and five, including the quarantined family, were from the Coimbatore rural limits. Four persons were residents of Chennai and another four belonged to Chengelput. One male passenger belonged to Palakkad in Kerala. Dr. Vijayalakshmi said he was contacted over phone and told to remain at home for a week and not to mingle with anyone in the neighbourhood. The local health authorities there were also informed. Of the 12 untraceable passengers, four were foreign nationals from Los Angeles, U.S. Efforts were on to locate them with the help of their contact numbers provided by the airport authorities in Chennai.
Swine flu cases in Tamilnadu
Swine Flu in Andhra Pradesh
DIPSAR - Admisssion 2009
Admission now open for Degree (B.Pharm) and Diploma (D.Pharm) courses at Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR) .
As per the directions given in the prospectus, report at the reception counter by 10:00 am on the specified dates. If any candidate is unable to report personally he/she may depute his/her relative with all relevant documents, fees etc.
List of original certificates required at the time of admission are :-
1. Marks statement of 10+2/Inter/12th Class
2. Date of Birth certificate
3. Provisional certificate from the last school attended
4. Character certificate from the school last attended
5. Proof of gap period, if any, after passing the 12th class
6. Medical certificate from a medical practitioner holding the degree not below MBBS.
7. Two passport size photographs (unattested, coloured)
8. Acknowledgment Slip
9. Reporting Slip
10. Caste certificate, if any issued from competent authority from Delhi only.
11. Any other certificate in respect of the claim made by the candidate.
DEGREE (B-Pharma) FEES (Rs
First year 16,500
Second year 12,000
Third year 15,000
Fourth year 14,000
D. Pharma FEES (Rs)
First year 10,000
Second year 8,000
Admission form for both the courses available here.
As per the directions given in the prospectus, report at the reception counter by 10:00 am on the specified dates. If any candidate is unable to report personally he/she may depute his/her relative with all relevant documents, fees etc.
List of original certificates required at the time of admission are :-
1. Marks statement of 10+2/Inter/12th Class
2. Date of Birth certificate
3. Provisional certificate from the last school attended
4. Character certificate from the school last attended
5. Proof of gap period, if any, after passing the 12th class
6. Medical certificate from a medical practitioner holding the degree not below MBBS.
7. Two passport size photographs (unattested, coloured)
8. Acknowledgment Slip
9. Reporting Slip
10. Caste certificate, if any issued from competent authority from Delhi only.
11. Any other certificate in respect of the claim made by the candidate.
DEGREE (B-Pharma) FEES (Rs
First year 16,500
Second year 12,000
Third year 15,000
Fourth year 14,000
D. Pharma FEES (Rs)
First year 10,000
Second year 8,000
Admission form for both the courses available here.
Tuesday, June 2, 2009
Amendments (proposed) in Indian Pharmacopoeia (IP) 2007
The Indian Pharmacopoeia Commission has received suggestions from stakeholders on standards to be complied with drugs included in the Indian Pharmacopoeia for time being in force and such other standards as prescribed from time to time by the Commission.
In order to adhere on the principle of “openness, justice and fairness” the feedback and inputs received from various users have been reviewed by the relevant Expert Subject Committee to ensure the feasibility and practibility of the standards and methods.
The draft amendments can be found here
Monographs to be incorporated in the coming edition of Indian Pharmacopoeia
The Indian Pharmacopoeia Commission is in the process of drafting the monographs approved by the Subject Expert Committee to be incorporated in the next edition of the IP. The stakeholders hereby requested to forward the draft monographs alongwith special features on standards which they deem appropriate for improving the quality of these drugs. The requisite details may be forwarded to Indian Pharmacopoeia Commission by the end of June 2009.
Amlodipine+Losartan
Anhydrous Lactose
Artesunate
Atorvastatin + Amlodipine
Benzoic Acid Solution
Betamethasone Dipropionate Cream
Betamethasone Dipropionate Lotion
Betamethsone Dipropionate Ointment
Bumetanide Tablets
Calcium Chloride Injection
Cefamandole Naftate
Cefoperazone+Sulbactum
Cetrimide Cream
Chlorothiazide
Chymotrypsin
Citicholine
Clindamycin
Clioquinol Cream
Clioquinol and Hydrocortisone Cream
Clioquinol and Hydrocortisone Ointment
Clioquinol Ointment
Codeine Phosphate Tablets
Cyproterone Acetate
Daunorubicin Hydrochloride
Dexchlorpheniramine Maleate
Dextropropoxyphene Capsules
Dextropropoxyphene Hydrochloride
Dextropropoxyphene Napsilate
Diacerin
Diazoxide
Diazoxide Tablets
Dicloxacillin Sodium
Dihydroergocristine Mesilate
Dihydroergotamine Mesylate
Disopyramide
Disopyramide Capsules
Disopyramide Phosphate Capsules
Disopyramide Phosphate Extended Release Capsules
Divalproex
Doxofylline
Enoxaparin
Ergocalciferol Injection
Ergocalciferol Tablets
Escitalopram
Estradiol and Norethisterone Acetate Tablets
Etodolac
Etodolac Capsules
Etodolac Tablets
Etoricoxib
Famotidine
Felodipine
Felodipine Extended Release Tablets
Fenbendazole
Fentanyl
Fentanyl Citrate
Ferrous Ascrobate+Folic Acid
Finasteride
Finasteride Tablets
Finofibrate
Fluconazole
Flucytosine
Flucytosine Tablets
Flucytosine Capsules
Flucytosine Oral Suspension
Flutamide
Flutamide Capsules
Gemifloxacin
Glibenclamide+Metformin
Gliclazide
Glimepride
Homatropine Methylbromide
Hyocyamine Sulphate
Ibuprofen Cream
Ibuprofen Gel
Indapamide Tablets
Ispaghula Husk Oral Powder
Lactulose
Lansoprazole
Linezolid
Lornoxicam
Losartan +Hydrochlorothiazide
Mecobalamin
Mefloquine Hydrochloride
Meloxicam Oral Suspension
Menthol and Benzoin Inhalation
Metronidazole Sterile Suspension
Miconazole
Mifepristone
Misoprostol
Mometasone
Montelukast
Naloxone Hydrochloride
Naloxone Injection
Naltrexone Hydrochloride
Naproxen
Naproxen Delayed Release Tablets
Naproxen Oral Suspension
Naproxen Sodium Tablets
Naproxen Suppositories
Naproxen Tablets
Ondansetron
Ondansetron Oral Solution
Ondansetron Orally Disintegrating Tablets
Ondensetron Hydrochloride Oral Suspension
Pantoprazole
Perphenazine
Perphenazine Tablets
Phenylpropanolamine Hydrochloride
Phenytoin
Pimozide
Piperacillin
Pravastatin sodium
Praziquantel
Praziquantel Tablets
Prednisolone Acetate
Pregabalin
Progesterone Injectable Suspension
Promazine Tablets
Propofol
Propofol Injection
Protriptyline Hydrochloride
Psyllium Hemicellulose
Psyllium Husk
Psyllium Hydrophillic Mucilloid for Oral Suspension
Psyllium Seed
Pyrimethamine Tablets
Rampril+Hydrochlorothiazide
Ribavirin
S-Amlodipine
Serratiopeptidase
Sildenafil
Simvastatin
Sumatriptan
Sumatriptan Injection
Telmisartan
Terazosin Hydrochloride Dihydrate
Ticarcillin and Clavullanic Acid for Injection
Ticarcillin and Clavullanic Acid Injection
Tolazamide
Tolnaftate
Tolnaftate Gel
Tolnaftate Cream
Tolnaftate Topical Powder
Tolnaftate Topical Solution
Tramadol
Trimetazidine
Valproic Acid
Valproic Acid Capsules
Valproic Acid Injection
Valproic Acid Oral Solution
Valsartan
Valsartan and Hydrochlorthiazide Tablets
Vancomycin Hydrochloride
Vancomycin Hydrochloride Capsules
Vancomycin Hydrochloride for Injection
Vancomycin Hydrochloride for Oral Solution
Vancomycin Injection
Vancomycin Intravenous Infusion
Voglibose
Amlodipine+Losartan
Anhydrous Lactose
Artesunate
Atorvastatin + Amlodipine
Benzoic Acid Solution
Betamethasone Dipropionate Cream
Betamethasone Dipropionate Lotion
Betamethsone Dipropionate Ointment
Bumetanide Tablets
Calcium Chloride Injection
Cefamandole Naftate
Cefoperazone+Sulbactum
Cetrimide Cream
Chlorothiazide
Chymotrypsin
Citicholine
Clindamycin
Clioquinol Cream
Clioquinol and Hydrocortisone Cream
Clioquinol and Hydrocortisone Ointment
Clioquinol Ointment
Codeine Phosphate Tablets
Cyproterone Acetate
Daunorubicin Hydrochloride
Dexchlorpheniramine Maleate
Dextropropoxyphene Capsules
Dextropropoxyphene Hydrochloride
Dextropropoxyphene Napsilate
Diacerin
Diazoxide
Diazoxide Tablets
Dicloxacillin Sodium
Dihydroergocristine Mesilate
Dihydroergotamine Mesylate
Disopyramide
Disopyramide Capsules
Disopyramide Phosphate Capsules
Disopyramide Phosphate Extended Release Capsules
Divalproex
Doxofylline
Enoxaparin
Ergocalciferol Injection
Ergocalciferol Tablets
Escitalopram
Estradiol and Norethisterone Acetate Tablets
Etodolac
Etodolac Capsules
Etodolac Tablets
Etoricoxib
Famotidine
Felodipine
Felodipine Extended Release Tablets
Fenbendazole
Fentanyl
Fentanyl Citrate
Ferrous Ascrobate+Folic Acid
Finasteride
Finasteride Tablets
Finofibrate
Fluconazole
Flucytosine
Flucytosine Tablets
Flucytosine Capsules
Flucytosine Oral Suspension
Flutamide
Flutamide Capsules
Gemifloxacin
Glibenclamide+Metformin
Gliclazide
Glimepride
Homatropine Methylbromide
Hyocyamine Sulphate
Ibuprofen Cream
Ibuprofen Gel
Indapamide Tablets
Ispaghula Husk Oral Powder
Lactulose
Lansoprazole
Linezolid
Lornoxicam
Losartan +Hydrochlorothiazide
Mecobalamin
Mefloquine Hydrochloride
Meloxicam Oral Suspension
Menthol and Benzoin Inhalation
Metronidazole Sterile Suspension
Miconazole
Mifepristone
Misoprostol
Mometasone
Montelukast
Naloxone Hydrochloride
Naloxone Injection
Naltrexone Hydrochloride
Naproxen
Naproxen Delayed Release Tablets
Naproxen Oral Suspension
Naproxen Sodium Tablets
Naproxen Suppositories
Naproxen Tablets
Ondansetron
Ondansetron Oral Solution
Ondansetron Orally Disintegrating Tablets
Ondensetron Hydrochloride Oral Suspension
Pantoprazole
Perphenazine
Perphenazine Tablets
Phenylpropanolamine Hydrochloride
Phenytoin
Pimozide
Piperacillin
Pravastatin sodium
Praziquantel
Praziquantel Tablets
Prednisolone Acetate
Pregabalin
Progesterone Injectable Suspension
Promazine Tablets
Propofol
Propofol Injection
Protriptyline Hydrochloride
Psyllium Hemicellulose
Psyllium Husk
Psyllium Hydrophillic Mucilloid for Oral Suspension
Psyllium Seed
Pyrimethamine Tablets
Rampril+Hydrochlorothiazide
Ribavirin
S-Amlodipine
Serratiopeptidase
Sildenafil
Simvastatin
Sumatriptan
Sumatriptan Injection
Telmisartan
Terazosin Hydrochloride Dihydrate
Ticarcillin and Clavullanic Acid for Injection
Ticarcillin and Clavullanic Acid Injection
Tolazamide
Tolnaftate
Tolnaftate Gel
Tolnaftate Cream
Tolnaftate Topical Powder
Tolnaftate Topical Solution
Tramadol
Trimetazidine
Valproic Acid
Valproic Acid Capsules
Valproic Acid Injection
Valproic Acid Oral Solution
Valsartan
Valsartan and Hydrochlorthiazide Tablets
Vancomycin Hydrochloride
Vancomycin Hydrochloride Capsules
Vancomycin Hydrochloride for Injection
Vancomycin Hydrochloride for Oral Solution
Vancomycin Injection
Vancomycin Intravenous Infusion
Voglibose
DIA - TN Chapter opening
The TN Chapter of the DIA proposes to host several lectures and seminars for members as Chapter activity .Moreover the Work shops and conferences will be at a discounted price to members .
The membership fee is Rs 800 to students, Rs 1200 for Academia , Rs 1600 for CRO, Industry ,others Please do send your staff and students and make the event a meaningful and interesting learning session.
Phase 1 Trials in India - The way forward ( Clinical,Ethical and Regulatory Issues) - Tuesday, 9th June 2009Inauguration - 10 min - 0900-0910
Session 1 - 0910- 1010 hrs
1. Overview of Phase 1 Clinical Trials - Dr Nadig( Crema) - 30min
2. Challenges in Phase 1 Trials- Dr Nadig ( Crema)- 20 min Q& A- 10 min
Session 2. - 10 10- 11 10 hrs
1.Clincal Trials& their Ethical Issues- 30min Dr Vasantha Muthuswamy ( former DDG - ICMR)2.Special Concerns in Phase 1 Clinical Trials - 20 min Dr Vasantha Muthuswamy
Q& A- 10min
TEA BREAK - 10 min
Session 3 - 1120- 1220 hrs
1. Regulatory Stand point of Phase 1 Trials in India.Dr Venkateswarlu ( Former DCGI)
2. Challenges in Global scenario vis-a-vis India Where are we and the way forward -Dr Venkateswarlu
DISCUSSION- 30 min 1220 - 1250
Concluding Remarks/PROFILE OF DIA - Dr Nandkumar Chodankar 1250- 1300
Time is not yet fixed - Depends on the auditorium availability 0900- 1300 hrs / or 1300- 17.00 hrs
Probable Venue would be Madras Diabetic Research Foundation.- Conran Smith Rd - in Golpalapuram near CM's house . Venue would be confirmed before June 5th which is the last date to send applications by all interested participants.
Participants who are interested to attend has to enroll for membership in DIA (Drug Information Association) . The application form can be found at http://ifile.%20it/k2xuv5b
Please do contact me if you need any further details
(1) Dr Annabelle Rajaseharan (Professor)9444066519 ; 984063661623751232(Res) after 5 pm (2) Dr Arun (PG student), Stanley Medical College, Chennai9841012335
(3) Dr Sreekanth Gattu (PG Student), SRMC, Chennai9940061168
The membership fee is Rs 800 to students, Rs 1200 for Academia , Rs 1600 for CRO, Industry ,others Please do send your staff and students and make the event a meaningful and interesting learning session.
Phase 1 Trials in India - The way forward ( Clinical,Ethical and Regulatory Issues) - Tuesday, 9th June 2009Inauguration - 10 min - 0900-0910
Session 1 - 0910- 1010 hrs
1. Overview of Phase 1 Clinical Trials - Dr Nadig( Crema) - 30min
2. Challenges in Phase 1 Trials- Dr Nadig ( Crema)- 20 min Q& A- 10 min
Session 2. - 10 10- 11 10 hrs
1.Clincal Trials& their Ethical Issues- 30min Dr Vasantha Muthuswamy ( former DDG - ICMR)2.Special Concerns in Phase 1 Clinical Trials - 20 min Dr Vasantha Muthuswamy
Q& A- 10min
TEA BREAK - 10 min
Session 3 - 1120- 1220 hrs
1. Regulatory Stand point of Phase 1 Trials in India.Dr Venkateswarlu ( Former DCGI)
2. Challenges in Global scenario vis-a-vis India Where are we and the way forward -Dr Venkateswarlu
DISCUSSION- 30 min 1220 - 1250
Concluding Remarks/PROFILE OF DIA - Dr Nandkumar Chodankar 1250- 1300
Time is not yet fixed - Depends on the auditorium availability 0900- 1300 hrs / or 1300- 17.00 hrs
Probable Venue would be Madras Diabetic Research Foundation.- Conran Smith Rd - in Golpalapuram near CM's house . Venue would be confirmed before June 5th which is the last date to send applications by all interested participants.
Participants who are interested to attend has to enroll for membership in DIA (Drug Information Association) . The application form can be found at http://ifile.%20it/k2xuv5b
Please do contact me if you need any further details
(1) Dr Annabelle Rajaseharan (Professor)9444066519 ; 984063661623751232(Res) after 5 pm (2) Dr Arun (PG student), Stanley Medical College, Chennai9841012335
(3) Dr Sreekanth Gattu (PG Student), SRMC, Chennai9940061168
Swine flu cases in Tamilnadu
Two confirmed cases of A (H1N1) influenza have been reported from Coimbatore in Tamil Nadu.
The patients — a 34-year-old woman and her five-year-old son — travelled to India from the United States via Dubai on May 28. They have been admitted to an identified facility in Coimbatore and put on Oseltamivir and are at present afebrile.
According to the Union Health and Family Welfare Ministry, all their local contacts have been traced, and their health status is being monitored. The passengers of the flights in which they travelled are being traced and have been advised to monitor their health. After reaching Chennai from the U.S. on May 28, they travelled to Coimbatore by a domestic flight the same day. They reported to the identified health facility as the child had fever before leaving the U.S.
Three cases so far
So far three A (H1N1) cases have been identified in the country, but these are people who had travelled to the affected countries. There has been no spread of the disease.
Screening of passengers from the affected countries is continuing at 21 international airports. Over 47,707 passengers were screened on June 1 and 21,274 of them were from the affected countries. A total of 221 doctors and 88 paramedics have been deployed to man 76 counters. Two passengers who arrived at the Delhi airport were shifted to the isolation facility.
Swine Flu in Andhra Pradesh
The patients — a 34-year-old woman and her five-year-old son — travelled to India from the United States via Dubai on May 28. They have been admitted to an identified facility in Coimbatore and put on Oseltamivir and are at present afebrile.
According to the Union Health and Family Welfare Ministry, all their local contacts have been traced, and their health status is being monitored. The passengers of the flights in which they travelled are being traced and have been advised to monitor their health. After reaching Chennai from the U.S. on May 28, they travelled to Coimbatore by a domestic flight the same day. They reported to the identified health facility as the child had fever before leaving the U.S.
Three cases so far
So far three A (H1N1) cases have been identified in the country, but these are people who had travelled to the affected countries. There has been no spread of the disease.
Screening of passengers from the affected countries is continuing at 21 international airports. Over 47,707 passengers were screened on June 1 and 21,274 of them were from the affected countries. A total of 221 doctors and 88 paramedics have been deployed to man 76 counters. Two passengers who arrived at the Delhi airport were shifted to the isolation facility.
Swine Flu in Andhra Pradesh
PCI issues notices to several pharmacy colleges in MP, Rajasthan
The Pharmacy Council of India (PCI) has issued show cause notices to several pharmacy colleges in Madhya Pradesh and Rajasthan for flouting rules in running these institutions. The PCI action comes after the surprise inspections carried out on pharmacy colleges in Madhya Pradesh and Rajasthan in which the PCI has found serious anomalies in the pharmacy colleges of these two states.
PCI chairman Dr B Suresh said that the PCI has issued notices to several pharmacy colleges in Madhya Pradesh and Rajasthan and has asked them to reply within one week before taking strict action against them. In the surprise inspections carried out by the PCI, it was found that these institutions are being run without proper faculty. Though these institutions have built the required building structures and deployed the required equipment, in the absence of faculty all these will remain show piece only, Dr Suresh said.
He said the PCI is waiting for the reply from these institutions before initiating action against these erring institutions for violating rules to run these institutions. The PCI has given them to explain one week's time after that the PCI will take action against them.
As part of its efforts to identify and clamp down on the pharmacy colleges which are hoodwinking the authorities by reportedly running without proper faculties, the PCI had recently started surprise inspections on the pharmacy colleges to verify the real picture in this regard. In the first phase, the surprise inspections were carried out in three states of Madhya Pradesh, Rajasthan and Andhra Pradesh. "In Andhra Pradesh, things are more or less ok, but there are serious violations, mostly severe shortage of faculty, in Rajasthan and Madhya Pradesh," Dr Suresh said.
The PCI chairman squarely blamed the AICTE for this mess as he said that the AICTE gives indiscriminate permission to start pharmacy colleges across the country without seriously verifying the availability of infrastructure, especially the faculty. He said that the main reason for this kind of practices by the educational institutions is the dual powers for regulating the pharma education in the country. At present, the pharmacy education is regulated by both the AICTE and the Pharmacy Council of India (PCI), a statutory body exclusively constituted for the pharmacy education in the country.
PCI chairman Dr B Suresh said that the PCI has issued notices to several pharmacy colleges in Madhya Pradesh and Rajasthan and has asked them to reply within one week before taking strict action against them. In the surprise inspections carried out by the PCI, it was found that these institutions are being run without proper faculty. Though these institutions have built the required building structures and deployed the required equipment, in the absence of faculty all these will remain show piece only, Dr Suresh said.
He said the PCI is waiting for the reply from these institutions before initiating action against these erring institutions for violating rules to run these institutions. The PCI has given them to explain one week's time after that the PCI will take action against them.
As part of its efforts to identify and clamp down on the pharmacy colleges which are hoodwinking the authorities by reportedly running without proper faculties, the PCI had recently started surprise inspections on the pharmacy colleges to verify the real picture in this regard. In the first phase, the surprise inspections were carried out in three states of Madhya Pradesh, Rajasthan and Andhra Pradesh. "In Andhra Pradesh, things are more or less ok, but there are serious violations, mostly severe shortage of faculty, in Rajasthan and Madhya Pradesh," Dr Suresh said.
The PCI chairman squarely blamed the AICTE for this mess as he said that the AICTE gives indiscriminate permission to start pharmacy colleges across the country without seriously verifying the availability of infrastructure, especially the faculty. He said that the main reason for this kind of practices by the educational institutions is the dual powers for regulating the pharma education in the country. At present, the pharmacy education is regulated by both the AICTE and the Pharmacy Council of India (PCI), a statutory body exclusively constituted for the pharmacy education in the country.
Subscribe to:
Posts (Atom)